These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35267437)

  • 1. Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group.
    González-Del-Alba A; Conde-Moreno AJ; García Vicente AM; González-Peramato P; Linares-Espinós E; Climent MÁ; The Sogug Multidisciplinary Working Group
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in the Management of Patients with Non-Muscle-Invasive Bladder Cancer Using a Multidisciplinary Approach: Practical Recommendations from the Spanish Oncology Genitourinary (SOGUG) Working Group.
    Rubio-Briones J; Algaba F; Gallardo E; Marcos-Rodríguez JA; Climent MÁ; On Behalf Of The Sogug Multidisciplinary Working Group
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group.
    Gómez Caamaño A; García Vicente AM; Maroto P; Rodríguez Antolín A; Sanz J; Vera González MA; Climent MÁ; On Behalf Of The Spanish Oncology Genitourinary Sogug Multisiciplinary Working Group
    Curr Oncol; 2021 Dec; 28(6):5084-5100. PubMed ID: 34940067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Bone Lesions with
    van Es SC; Velleman T; Elias SG; Bensch F; Brouwers AH; Glaudemans AWJM; Kwee TC; Iersel MW; Maduro JH; Oosting SF; de Vries EGE; Schröder CP
    J Nucl Med; 2021 Feb; 62(2):177-183. PubMed ID: 32817140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting.
    Garrido Siles M; López-Beltran A; Pelechano P; García Vicente AM; Gironés Sarrió R; González-Haba Peña E; Rodríguez Antolín A; Zapatero A; Arranz JÁ; Climent MÁ;
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?
    Pagani O; Senkus E; Wood W; Colleoni M; Cufer T; Kyriakides S; Costa A; Winer EP; Cardoso F;
    J Natl Cancer Inst; 2010 Apr; 102(7):456-63. PubMed ID: 20220104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.
    Gauvin C; Krishnan V; Kaci I; Tran-Thanh D; Bédard K; Albadine R; Leduc C; Gaboury L; Blais N; Tehfe M; Routy B; Florescu M
    Curr Oncol; 2021 Jan; 28(1):593-605. PubMed ID: 33498159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG).
    Font A; Luque R; Villa JC; Domenech M; Vázquez S; Gallardo E; Virizuela JA; Beato C; Morales-Barrera R; Gelabert A; Maciá S; Puente J; Rubio G; Maldonado X; Perez-Valderrama B; Pinto A; Fernández Calvo O; Grande E; Garde-Noguera J; Fernández-Parra E; Arranz JÁ
    Target Oncol; 2019 Feb; 14(1):15-32. PubMed ID: 30694442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.
    Sternberg CN; Donat SM; Bellmunt J; Millikan RE; Stadler W; De Mulder P; Sherif A; von der Maase H; Tsukamoto T; Soloway MS
    Urology; 2007 Jan; 69(1 Suppl):62-79. PubMed ID: 17280909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
    Miyawaki T; Kenmotsu H; Harada H; Ohde Y; Chiba Y; Haratani K; Okimoto T; Sakamoto T; Wakuda K; Ito K; Uemura T; Sakata S; Kogure Y; Nishimura Y; Nakagawa K; Yamamoto N
    BMC Cancer; 2021 Oct; 21(1):1121. PubMed ID: 34663250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Kollberg P; Almquist H; Bläckberg M; Cwikiel M; Gudjonsson S; Lyttkens K; Patschan O; Liedberg F
    Scand J Urol; 2017 Aug; 51(4):308-313. PubMed ID: 28532260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
    Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
    Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
    Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
    Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma.
    Girard A; Vila Reyes H; Shaish H; Grellier JF; Dercle L; Salaün PY; Delcroix O; Rouanne M
    Front Oncol; 2020; 10():565086. PubMed ID: 33117695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer.
    Beigi A; Vafaei-Nodeh S; Huang L; Sun SZ; Ko JJ
    Curr Oncol; 2021 Sep; 28(5):3812-3824. PubMed ID: 34677243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
    Wei XX; Werner L; Teo MY; Rosenberg JE; Koshkin VS; Grivas P; Szabados B; Morrison L; Powles T; Carril-Ajuria L; Castellano D; Velho PI; Hahn NM; McKay RR; Raggi D; Necchi A; Kanesvaran R; Alerasool P; Gaines J; Galsky M; Bellmunt J; Sonpavde G
    J Urol; 2021 Feb; 205(2):414-419. PubMed ID: 32935617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.